Larimar announced that it will provide a nomlabofusp development program update in mid-December 2024 that will include available safety, PK and frataxin data, as well as available clinical outcomes observations from patients currently receiving a daily 25 mg dose of nomlabofusp for approximately 30 to 180 days in the OLE study. An update on enrollment in the OLE study will also be provided.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics initiated with an Outperform at Oppenheimer
- Larimar Therapeutics initiated with an Outperform at Wedbush
- Wedbush bullish on Larimar Therapeutics, initiates with an Outperform
- Larimar Therapeutics initiated with a Buy at H.C. Wainwright
- Larimar Therapeutics initiated with a Buy at JonesResearch